Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of SAP-001 in Renal Impairment
NCT06729853Phase 2Active, not recruiting
- Sponsor
- Shanton Pharma
- Start
- Apr 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of sap-001 in gout and hyperuricemia (4 arms), sponsored by Shanton Pharma. Primary endpoints: Maximum observed concentration at Day 8, Area under the concentration-time curve from time 0 to time of last quantifiable sample at Day 8 and 1 more. Started Apr 2024; status: active, not recruiting.
02
Drugs
sap-001
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT06729853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06729853.